Showing results (51-60 of 138) with videos related to
Sort By:
Pageof 14
Onkologie|April 1, 1982
[Treatment of refractory cytostatic agent-induced vomiting with the synthetic cannabinoid levonantradol]M E Heim, W QueisserOnkologie|August 1, 1989
Combined modality of radiation and chemotherapy for the treatment of gastric carcinoma. A reviewW Queisser, M E HeimThrombosis and Haemostasis|December 22, 1988
Monitoring of heparin and low molecular weight heparin with capillary and venous whole bloodJ Harenberg, C Giese, C E Dempfle, et al.Annals of the New York Academy of Sciences|June 18, 1999
Evaluation of systolic performance by automated impedance cardiographyA W Scherhag, J Stastny, S Pfleger, et al.Thrombosis and Haemostasis|December 20, 1993
Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparinsJ Harenberg, M Siegele, C E Dempfle, et al.Seminars in Thrombosis and Hemostasis|January 1, 1997
Anticoagulation in patients with heparin-induced thrombocytopenia type IIJ Harenberg, G Huhle, L Piazolo, et al.Thrombosis and Haemostasis|April 30, 1976
Studies on chemically modified fibrinogenM Kloczewiak, Z Wegrzynowicz, F R Matthias, et al.European Journal of Drug Metabolism and Pharmacokinetics|January 1, 1987
Pharmacokinetics of n-propyl-ajmaline-bitartrate in elderly patients with ventricular ectopic activityR Elfner, G Achtert, H J Hausleiter, et al.Thrombosis and Haemostasis|June 30, 1989
Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteersJ Harenberg, C Giese, C E Dempfle, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 1, 1995
Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assayJ Harenberg, B Haaf, C E Dempfle, et al.Pageof 14